Edgewise Therapeutics (EWTX) Cash from Investing Activities (2020 - 2026)

Edgewise Therapeutics (EWTX) has 7 years of Cash from Investing Activities data on file, last reported at $2.4 million in Q1 2026.

• For the quarter ending Q1 2026, Cash from Investing Activities fell 94.46% year-over-year to $2.4 million; the trailing twelve-month figure through Mar 2026 stood at -$74.3 million (down 158.22% YoY), and the FY2025 full-year result was -$32.8 million, up 82.24% from the prior year.
• Cash from Investing Activities slipped to $2.4 million in Q1 2026, from $49.8 million in the prior quarter.
• In the past five years, Cash from Investing Activities ranged from a high of $49.8 million in Q4 2025 to a low of -$268.3 million in Q1 2024.
• A 5-year average of -$10.7 million and a median of $23.4 million in 2023 frame the typical range for Cash from Investing Activities.
• Across the five-year window, Cash from Investing Activities soared 7582.61% in 2023 and slumped 647.1% in 2024, its largest moves.
• Tracing EWTX's Cash from Investing Activities over 5 years: stood at -$75.6 million in 2022, then soared by 135.69% to $27.0 million in 2023, then retreated by 22.46% to $20.9 million in 2024, then soared by 137.85% to $49.8 million in 2025, then tumbled by 95.11% to $2.4 million in 2026.
• Business Quant data shows EWTX's Cash from Investing Activities at $2.4 million in Q1 2026, $49.8 million in Q4 2025, and $35.7 million in Q3 2025.